Targets targeted by Erdafitinib
Erdafitinib (Erdafitinib) is a small molecule targeted drug. Its main function is to interfere with the proliferation and survival of cancer cells by inhibiting the activity of fibroblast growth factor receptor (FGFR). FGFR is a type of membrane receptor tyrosine kinase that participates in important processes such as cell growth, differentiation and survival.
The targets of Erdafitinib mainly includeFGFR1, FGFR2, FGFR3 and FGFR4. These receptors play key physiological roles in normal cells, but in some cancers, they may be overexpressed, mutated, or activated, leading to abnormal signaling pathway activity, thereby promoting the proliferation and survival of cancer cells.

By inhibiting FGFR, erdafitinib interferes with the FGFR signaling pathway and blocks abnormally active signaling, thus preventing the uncontrolled growth of cancer cells. This precise targeted therapy can reduce the impact on normal cells and is more targeted and selective than traditional cancer treatments.
It is worth noting that because FGFR plays a role in a variety of cancers, erdafitinib is currently mainly studied and approved for the treatment of advanced or metastatic urothelial carcinoma (UC). However, as research continues, further exploration and research into the efficacy and safety of this drug in other cancer types may also be conducted. Patients should consult their physician for professional advice and guidance before using erdafitinib or any other drug.
Erdafitinib is not currently available in the country, so patients cannot purchase it domestically and need to purchase erdafitinib through foreign channels. The original drug of erdafitinib is mainly the Hong Kong version of the original drug, with a price of more than 20,000, and needs to be purchased through a Hong Kong pharmacy. The generic drugs are relatively cheaper, mainly the Laos version and the Bangladesh Yaopin International version, with a price of about 1,000 to 2,000, and the ingredients of the original drug and the generic drug are basically the same.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)